Cangrelor in Comatose Survivors of OHCA Undergoing Primary PCI

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of the trial is to find out if 4-hour continuous infusion of parenteral P2Y12 inhibitor cangrelor at the start of primary percutaneous coronary intervention (PCI) immediately and effectively suppresses platelet activity in comatose survivors of out-of-hospital cardiac arrest (OHCA). Half of the participants will receive the standard care of dual antiplatelet therapy - acetysalicylic acid and ticagrelor tablets via nasogastric or orogastric tube and the other half the standard care with additional cangrelor infusion at the start of the PCI.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Medical Centre Ljubljana
• Collaborator: Chiesi Slovenija, d.o.o.
• Treatments: Cangrelor; Ticagrelor

Criteria

Inclusion Criteria:

• age 18 to 70 years

• comatose survivors of out-of-hospital cardiac arrest undergoing primary percutaneous coronary intervention

• treatment with induced therapeutic hypothermia

• no contraindication for dual antiplatelet therapy

Exclusion Criteria:

• pregnancy

• patients without return of spontaneous circulation or patients on ECMO

• history of recent P2Y12 use (last 7 days)

• history of recent vitamin K antagonist or NOAC use (last 14 days)

• active bleeding

• history of transient ischemic attack or cerebral vascular insult

• strong bleeding tendency (Child C liver cirrhosis, stage IV-V chronic renal disease)

• history of allergic reactions to acetylsalicylic acid, heparin or P2Y12 inhibitors

• terminal disease or life expectancy less than 1 year